Mohamed M Swidan1, Omnya M Khowessah2, Mohamed Abd El-Motaleb3, Ahmed Abd El-Bary2, Mohamed T El-Kolaly3, Tamer M Sakr4,5. 1. Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt. dr_swidan@yahoo.com. 2. Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, PO11562, Cairo, Egypt. 3. Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt. 4. Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, PO13759, Cairo, Egypt. Tamer_sakr78@yahoo.com. 5. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Modern Sciences and Arts University, 6th October City, Egypt. Tamer_sakr78@yahoo.com.
Abstract
BACKGROUND: The evolution of nanoparticles has gained prominence as platforms for developing diagnostic and/or therapeutic radiotracers. This study aims to develop a novel technique for fabricating a tumor diagnostic probe based on iron oxide nanoparticles excluding the utilization of chelating ligands. METHODS: Tc-99 m radionuclide was loaded into magnetic iron oxide nanoparticles platform (MIONPs) by sonication. 99mTc-encapsulated MIONPs were fully characterized concerning particles size, charge, radiochemical purity, encapsulation efficiency, in-vitro stability and cytotoxicity. These merits were biologically evaluated in normal and solid tumor bearing mice via different delivery approaches. RESULTS: 99mTc-encapsulated MIONPs probe was synthesized with average particle size 24.08 ± 7.9 nm, hydrodynamic size 52 nm, zeta potential -28 mV, radiolabeling yield 96 ± 0.83%, high in-vitro physiological stability, and appropriate cytotoxicity behavior. The in-vivo evaluation in solid tumor bearing mice revealed that the maximum tumor radioactivity accumulation (25.39 ± 0.57, 36.40 ± 0.59 and 72.61 ± 0.82%ID/g) was accomplished at 60, 60 and 30 min p.i. for intravenous, intravenous with physical magnet targeting and intratumoral delivery, respectively. The optimum T/NT ratios of 57.70, 65.00 and 87.48 were demonstrated at 60 min post I.V., I.V. with physical magnet targeting and I.T. delivery, respectively. These chemical and biological characteristics of our prepared nano-probe demonstrate highly advanced merits over the previously reported chelator mediated radiolabeled nano-formulations which reported maximum tumor uptakes in the scope of 3.65 ± 0.19 to 16.21 ± 2.56%ID/g. CONCLUSION: Stabilized encapsulation of 99mTc radionuclide into MIONPs elucidates a novel strategy for developing an advanced nano-sized radiopharmaceutical for tumor diagnosis. Graphical abstract 99mTc-encapsulated MIONPs nanosized-radiopharmaceutical as molecular imaging probe for tumor diagnosis.
BACKGROUND: The evolution of nanoparticles has gained prominence as platforms for developing diagnostic and/or therapeutic radiotracers. This study aims to develop a novel technique for fabricating a tumor diagnostic probe based on iron oxide nanoparticles excluding the utilization of chelating ligands. METHODS:Tc-99 m radionuclide was loaded into magnetic iron oxide nanoparticles platform (MIONPs) by sonication. 99mTc-encapsulated MIONPs were fully characterized concerning particles size, charge, radiochemical purity, encapsulation efficiency, in-vitro stability and cytotoxicity. These merits were biologically evaluated in normal and solid tumor bearing mice via different delivery approaches. RESULTS: 99mTc-encapsulated MIONPs probe was synthesized with average particle size 24.08 ± 7.9 nm, hydrodynamic size 52 nm, zeta potential -28 mV, radiolabeling yield 96 ± 0.83%, high in-vitro physiological stability, and appropriate cytotoxicity behavior. The in-vivo evaluation in solid tumor bearing mice revealed that the maximum tumor radioactivity accumulation (25.39 ± 0.57, 36.40 ± 0.59 and 72.61 ± 0.82%ID/g) was accomplished at 60, 60 and 30 min p.i. for intravenous, intravenous with physical magnet targeting and intratumoral delivery, respectively. The optimum T/NT ratios of 57.70, 65.00 and 87.48 were demonstrated at 60 min post I.V., I.V. with physical magnet targeting and I.T. delivery, respectively. These chemical and biological characteristics of our prepared nano-probe demonstrate highly advanced merits over the previously reported chelator mediated radiolabeled nano-formulations which reported maximum tumor uptakes in the scope of 3.65 ± 0.19 to 16.21 ± 2.56%ID/g. CONCLUSION: Stabilized encapsulation of 99mTc radionuclide into MIONPs elucidates a novel strategy for developing an advanced nano-sized radiopharmaceutical for tumor diagnosis. Graphical abstract 99mTc-encapsulated MIONPs nanosized-radiopharmaceutical as molecular imaging probe for tumor diagnosis.
Entities:
Keywords:
Chelator free radiolabeling; Encapsulation; Magnetic iron oxide nanoparticles; Tc-99 m radionuclide; Tumor delivery; Tumor diagnosis
Authors: Grace Hu; Michal Lijowski; Huiying Zhang; Kathryn C Partlow; Shelton D Caruthers; Garry Kiefer; Gyongyi Gulyas; Phillip Athey; Michael J Scott; Samuel A Wickline; Gregory M Lanza Journal: Int J Cancer Date: 2007-05-01 Impact factor: 7.396
Authors: Amir R Jalilian; Blanca Ocampo-García; Wanvimol Pasanphan; Tamer M Sakr; Laura Melendez-Alafort; Mariano Grasselli; Ademar B Lugao; Hassan Yousefnia; Clelia Dispenza; Siti Mohd Janib; Irfan U Khan; Michał Maurin; Piotr Ulański; Say Chye Joachim Loo; Agnes Safrany; Joao A Osso; Adriano Duatti; Kattesh V Katti Journal: Pharmaceutics Date: 2022-05-15 Impact factor: 6.525